Capivasertib is an AKT inhibitor designed for the treatment of HR /HER2breast cancer that exhibits alterations in the PIK3CA/AKT1/PTEN pathway. It blocks AKT signaling, which is super important for how cancer cells grow and multiply. You can get it in two doses – either 200 mg or 400 mg in tablet form.
The normal dose is 400 mg, taken twice a day for four days, then you take a break for three days. The drug comes in bottles with 64 tablets. One bottle lasts for a full seven-day cycle.
Then, you repeat the cycle if you need more.
Reviews
There are no reviews yet.